Abstract:
Natural Killer (NK) cell activity of peripheral blood mononuclear cells (PBMC) against K562 myeloid cells was studied in six normal heterosexual men and six patients with acquired immune deficiency syndrome (AIDS). The mean NK cell activity in six patients with AIDS was 28.74 +/- 6.82% (SEM) compared with 47.24 +/- 7.26% in six normal heterosexual men (p less than 0.10). PBMC obtained from these subjects were incubated overnight in complete medium alone, complete medium supplemented with interferon-alpha 2 (IFN-alpha 2), complete medium supplemented with interleukin-2 (IL-2), and complete medium supplemented with both IFN-alpha 2 and IL-2. Incubation of PBMC with IFN-alpha 2 enhanced the NK cell activity significantly (73.07 +/- 4.22%, p less than 0.025) in normal heterosexual men, but not in patients with AIDS (38.22 +/- 7.10%, p greater than 0.05). In contrast, IL-2 significantly enhanced NK cell activity in both patients with AIDS (57.16 +/- 8.4%, p less than 0.05) and normal heterosexual men (71.58 +/- 5.87%, p less than 0.05). When PBMC from both groups of subjects were incubated with both IFN-alpha 2 and IL-2, the NK cell activity increased to levels higher than those seen with either IFN-alpha 2 or IL-2 alone. These results suggest that IL-2 is capable of augmenting in vitro NK cell-mediated cytotoxicity with cells from AIDS patients.
Keywords: Acquired Immunodeficiency Syndrome/*IMMUNOLOGY Adult Cytotoxicity, Immunologic Human Interferon Type I/*IMMUNOLOGY Interleukin-2/*IMMUNOLOGY Killer Cells, Natural/*IMMUNOLOGY Male JOURNAL ARTICLE
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1985. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.
